Future studies evaluating the effects of more specific IDO inhibitors on renal tissue are needed to establish if IDO (-1 and/or−2) inhibition may be beneficial for SLE patients suffering from glomerulonephritis. Here, IDO1 is linked to systemic lupus erythematosus.